Iqvia vs Labcorp
IQV and LH side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IQV and LH compare
Iqvia is the larger company, worth 1.4 times as much as Labcorp ($42.5B against $30.2B).
On earnings, Labcorp is cheaper: it trades at 30.6× trailing earnings, against 31.3× for Iqvia.
Iqvia grew revenue faster over the last twelve months (8.8% versus 6.0% for Labcorp).
Iqvia keeps more of each dollar of sales as profit, with a net margin of 8.1% compared with 6.9% at Labcorp.
Labcorp pays a dividend yielding 0.77%; Iqvia does not pay one.
Labcorp scores higher on the StockData Score (11 against 9 for Iqvia), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IQV | LH |
|---|---|---|
| Size and price | ||
| Market cap | $42.5B | $30.2B |
| Share price | $257.60 | $372.46 |
| Change, 1 year | 16.8% | 39.0% |
| Change, 5 years | −1.7% | 28.7% |
| Beta (5Y) | 0.63 | −0.07 |
| Employees | 93K | 71K |
| StockData Score | ||
| Total score | 9 | 11 (better) |
| Valuation score | 2 (better) | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 4 (better) | 2 |
| Health score | 0 | 4 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | 31.3× | 30.6× (better) |
| P/S | 2.5× | 2.1× (better) |
| P/B | 6.4× | 3.4× (better) |
| EV/EBITDA | 16.4× | 16.2× (better) |
| P/FCF | 20.4× (better) | 23.5× |
| PEG | 2.82 | – |
| FCF yield | 4.9% (better) | 4.3% |
| Fair value | $226.21 | $320.16 |
| Margin of safety | −13.9% (better) | −16.3% |
| Growth | ||
| Revenue growth (TTM) | 8.8% (better) | 6.0% |
| Revenue growth, 5Y average | 7.5% (better) | −0.04% |
| Net income growth (TTM) | 8.7% | 17.4% (better) |
| EPS growth (TTM) | 12.9% | 19.6% (better) |
| EPS growth, 5Y average | 40.5% (better) | −8.0% |
| Profitability | ||
| Gross margin | 33.1% (better) | 29.0% |
| Operating margin | 12.8% (better) | 10.3% |
| Net margin | 8.1% (better) | 6.9% |
| FCF margin | 12.0% (better) | 8.8% |
| Return on equity | 21.7% (better) | 11.4% |
| Return on invested capital | 9.4% (better) | 8.6% |
| Financial health | ||
| Debt / equity | 2.41 | 0.66 (better) |
| Net debt / EBITDA | 3.97 | 2.53 (better) |
| Interest coverage | 2.8× | 6.5× (better) |
| Current ratio | 0.83 | 1.41 (better) |
| Altman Z-score | 2.21 | 3.57 (better) |
| Piotroski F-score | 6 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.77% |
| Payout ratio | – | 23.6% |
| Years of dividend growth | – | 0 |
| Buyback yield | 2.7% (better) | 2.2% |
| Shareholder yield | 2.7% | 3.0% (better) |
| Ownership | ||
| Held by institutions | 95.2% | 97.9% |
| Held by insiders | 1.1% | 0.39% |
| Insider net buying, 12 months | −$39.3M | −$11.7M (better) |
| Superinvestors holding | 3 (better) | 1 |
| Short interest, % of float | 1.9% | 3.1% |
Go deeper
- IQV stock overview
- IQV income statement
- IQV valuation and score
- LH stock overview
- LH income statement
- LH valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.